In the last year, several medtech firms secured substantial investment rounds to bolster their innovative projects. Pulsed-field ablation, brain-computer interfaces (BCIs), AI-driven surgical software, and more technologies attracted significant funding in 2024. This year saw a notable number of companies receiving over $100 million in a single funding round.
Here are the top medtech funding rounds in 2024, each securing $100 million or more:
1. Blackrock Neurotech — $200 Million
In April, Tether, a cryptocurrency developer, invested $200 million in Blackrock Neurotech, making it the majority stakeholder. Blackrock, known for its NeuroPort Array neural interface, aids patients in regaining agency over physical and digital interfaces despite neurological disorders.
2. Oura — $200 Million
Smart ring manufacturer Oura culminated the year by closing a $200 million round led by Dexcom, aimed at combining health-tracking technology with glucose monitoring insights.
3. Kestra Medical — $196 Million
Kestra’s Assure system, a wearable defibrillator, received a $196 million boost in July as it continues to cater to underrepresented female cardiac patients with venture detection technology.
4. Caresyntax — $180 Million
Striving to refine surgical precision, Caresyntax enhanced its Series C funding with a total of $180 million to innovate its end-to-end AI surgery platform, boosting operational efficacy for better outcomes.
5. Imperative Care — $150 Million
July spotlighted Imperative Care as it gathered $150 million to excel in stroke intervention and vascular disease treatment, among other health initiatives.
6. Insightec — $150 Million
With $150 million raised, Insightec is advancing its ultrasound-guided neurosurgery tools, celebrated for efficacy in treating disorders like essential tremor and Parkinson’s disease.
7. Impulse Dynamics — $136 Million
Securing $136 million in February, Impulse Dynamics plans to expand its cardiac modulation therapies to dramatically enhance heart contraction and blood oxygenation in patients.
8. Mainstay Medical — $125 Million
Mainstay Medical is channeling this $125 million investment to commercialize its ReActiv8 neurostimulation system for chronic low back pain across the U.S. and internationally.
9. Capstan Medical — $110 Million
Capstan Medical’s ambition is to revolutionize minimally invasive heart valve replacement procedures; the $110 million funding came just as they neared pivotal trials.
10. Magenta Medical — $105 Million
Elevate, Magenta’s miniature heart pump, garnered $105 million to expedite its clinical application, including hopes to enter the U.S. market soon.
11. Kardium — $104 Million
In June, Kardium’s innovative Globe system for rapid heart mapping and ablation was bolstered by a $104 million investment to scale its clinical reach.
12. HistoSonics — $102 Million
Specializing in non-invasive liver tumor treatment, HistoSonics secured $102 million to advance its unique histotripsy technology to market readiness.
13. Precision Neuroscience — $102 Million
Join the high-buzz BCI sector, Precision Neuroscience’s thin-film brain implant advances were backed by a $102 million funding round.
14. Amber Therapeutics — $100 Million
Amber Therapeutics landed $100 million with its groundbreaking adaptive neuromodulation tech, targeting urinary incontinence treatment for women globally.